Lieutenant Colonel Kevin Weil emerging from stealth with $215m in funding from a Series A! Warp Sciences is using AI and robots to make and test molecules for companies developing new drugs. He was OpenAI CPO, and was leading AI-for-science before he left to found Warp.
Warp Sciences raises $215M Series A to apply AI and robotics to drug discovery
AIWarp Sciences, founded by former OpenAI CPO Kevin Weil, emerged from stealth with a $215M Series A led by Lightspeed. The company plans to make and test molecules for drug developers using AI and robotics, starting as a preclinical contract research organization in America.
AIWhy it matters.
The post reports a $215M Series A for a company combining AI and robotics in drug testing, with its founder's OpenAI background explaining why the venture is notable.
Andrew CurranVerified on X
@AndrewCurran_
💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster. We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America. I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.View quoted post on X
Source details
Andrew Curran · x.comPublished · added here
Original title: Lieutenant Colonel Kevin Weil emerging from stealth with $215m in funding from a Series A! Warp Sciences is using AI and robots to make a...